Skip to content
The Policy VaultThe Policy Vault

octreotide acetate injection — CareFirst (Caremark)

Congenital hyperinsulinism (CHI)

Initial criteria

  • Treatment of congenital hyperinsulinism or persistent hyperinsulinemic hypoglycemia in an infant

Approval duration

6 months